Introduction:

Epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) and primary peritoneal carcinomatosis (PPC) are associated with poor prognosis, and up to 15% of cases are hereditary. cytoreductive surgery (CRS) and platinum-based chemotherapy are the cornerstones of the treatment.

Material and methods:

We performed a retrospective study of a series of 43 consecutive cases using the Tumor Registry Database of our center, with the objective of determining progression-free survival (PFS) and overall survival (OS) in real life (primary end points); as well as post-progression survival (PPS) and the proportion of patients with germline mutations in genes related to hereditary EOC (secondary end points).

Results:

In our study, median PFS was 53 months, with a probability of PFS at 1, 3 and 5 years of 84, 54 and 40%, respectively. Median OS had not been reached, and the probability of OS at 1, 3 and 5 years was 89, 82 and 64%, respectively. Median PPS was 60 months, and the probability of 5-year PPS was 43%. A total of 7 patients (16.3%) had pathogenic germline mutations: three patients (6.9%) in the BRCA-2 gene; two (4.7%) in the BRCA-1 gene, one (2.3%) in the ATM gene and another in the MUTYH gene (2.3%).

Conclusions:

Our study demonstrates the importance of CRS and platinum-based chemotherapy in patients with EOC, FTC and PPC in the clinical practice; and highlights the relevance of genetic counseling in these patients.

        · resumen en Español     · texto en Español     · Español ( pdf )